Indication
Spontaneous Bacterial Peritonitis
6 clinical trials
10 products
1 drug
Clinical trial
Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial PeritonitisStatus: Not yet recruiting, Estimated PCD: 2024-12-31
Product
20% High Dose AlbuminProduct
20% Reduced Dose AlbuminClinical trial
Doxycycline for the Prevention of Spontaneous Bacterial PeritonitisStatus: Completed, Estimated PCD: 2020-08-07
Product
doxycyclineClinical trial
Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial): a Randomized Control TrialStatus: Not yet recruiting, Estimated PCD: 2024-12-31
Product
RifaximinProduct
NorfloxacinClinical trial
Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With CiprofloxacinStatus: Completed, Estimated PCD: 2023-11-30
Product
CiprofloxacinClinical trial
Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in CirrhosisStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Co-TrimoxazoleProduct
PlaceboClinical trial
The Potential Role of Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis: A Quadruple Blind Clinical StudyStatus: Recruiting, Estimated PCD: 2024-04-25
Product
AllopurinolProduct
AtorvastatinDrug
Varlilumab